2024 Pitchers

Home » 2024 Pitchers

Start-up Slams

They will pitch at BioFIT 2024:

Tuesday, December 3^rd | 9.45 – 10.45 am

DIAGNOSTIC

FLUONIR
NIR-II Fluorescence | Fluorescence-Guided Surgery | Cancer Diagnosis and Treatment

BeLiver
Liver Cancer | Treatment Prediction | MedTech

Damocles Diagnostics
Rapid Diagnostics | Antibiotic Resistance | Point of Care

METABOLIC DISEASES

V4CURE
Drug | Aquaretic | Cardio-renal pathologies

Tuesday, December 3^rd | 2.00 – 3.45 pm

ONCOLOGY

Hemerion Therapeutics
Oncology | Neurology | Drug-Device Combo

CasInvent Pharma
Resistance in Cancer | New Mechanism to Fight Resist | AML – Venetovclax, PDAC Chemo

PepKon
Peptides | Oncology | First in Class

Starkage Therapeutics
Senescence | Oncology | ADC

Actipulse Neuroscience
Blood-Brain Barrier | Non-Invasive Neuromodulation | CNS Drug Delivery

Simmunext Biotherapeutics
Immunofilaments | Immunotherapy for Cancer | Bioconjugate

GlycoTherapeutics
Oncology | Glycobiology | Small Molecule

Wednesday, December 4^th | 9.45 – 10.45 am

CNS

InBrain Pharma
Dopamine Based DAT | Device Aided Therapy | Advanced Parkinson Disease

IPCURE
Dementia | Drug Development | Small Peptidomimetics

CELL & GENE THERAPY

ABLEVIA
Anti-Drug Antibody Removal | Orphan Diseases | Gene Therapy Vectors

Wednesday, December 4^th | 2.00 – 3.00 pm

ENABLING TECHNOLOGIES

IRUBIS
Bioprocessing | Spectroscopy | Process Analytical Technology

BiomimX
Mechanical Stimulation | 3D Human Tissues | Drug Safety/Efficacy

Biotactical
Sterility Testing | Bioluminescence | ATMP

GoodBot
Lab Automation | Liquid Handling | Pipetting Robot

Collaborative and licensing opportunity presentations

They will pitch at BioFIT 2024:

Tuesday, December 3^rd | 11.00 am – 12.30 pm

DIAGNOSTIC

Panadea Diagnostics
Antibody test | Highly specific | Multi-species

Biogem
Biosensor | Oncology | Diagnosis

IMMUNOLOGY

Institut Pasteur
Human Immune Response | 1,000-person cohort | Personalized Medicine

Lutech – Allergimmune
Adjuvant | Allergy | Immunotherapy

ONCOLOGY – DRUG DISCOVERY

European Institute of Oncology (IEO) – EPIKIN
Clinical Kinase Inhibitors | Unbiased Functional Profiling | High-throughput platform

ONCOLOGY

Brenus Pharma
Precision immuno-oncology | Active proteomic immunotherapies | Deep-tech biotechnology

Wednesday, December 4^th | 11.00 am – 12.30 pm

CELL & GENE THERAPY

Fondazione Telethon – THE FUTURE OF GENE THERAPY
Gene editing | Mobilisation conditioning | HSPC

IRCCS Ospedale Galeazzi – PCART-PROGENITOR CARTILAGE CELLS
Osteoarthritis | Regenerative Medicine | Cartilage

bespark*bio
Gene therapy | Enabling Technology | Viral Vector

CNS

Okinawa Institute
Alzheimer | Peptide drug | Tau

SATT Linksium – ASTROPROTECT
Alzheimer Disease | Neuroprotection | TRPA1

SATT AxLR – WOLTHER
Wolfram Syndrome | Alzheimer Disease | Sigma-1 agonists

DRUG DISCOVERY

Nebula
Generative AI | Drug targets discovery | Protein dynamics

Animal Health Presentations

The Animal Health Presentations focus on innovations in relation to animal well-being and health.

Co-organised by:

They will pitch at BioFIT 2024:

Tuesday, December 3^rd | 4.15 – 5.00 pm

ANIMAL HEALTH

BENNO THERAPEUTICS
Vaccine | Canine cancer | Tumor vasculature

DAMOCLES DIAGNOSTICS – DAMAST
Point of Care | Diagnostic test | Fast AST

FINDIMMUNE – WOOF
Oral melanoma | Squamous cell carcinoma | Immunotherapy

INRAE TRANSFERT
SVCV | Vaccine platform | Host-pathogen model

Tuesday, December 3^rd | 5.15 – 6.00 pm

INRAE TRANSFERT
Influenza A virus | Vaccine | H5N1

GHENT UNIVERSITY
Bacterial infections | Antibiotic resistance | Pyoderma

VAXINANO
Nasal vaccines | Delivery system | Platform

AIHERD
Dairy | Monitoring | Detection

Alexandre Breda, Biotech Start-up Manager, Eurasanté
Gary Breit, CEO, Breit Ideas LLP
Vincent Brichard, Venture Partner, EQT Life Sciences
Zuzanna Brzosko, Senior Director, Corporate Strategy & External Innovation, Eli Lilly and Company
Ivan Burkov, Principal, Inkef
Florence Dal Degan, Senior Director, External Innovation, Rare Diseases and Neuroscience, Ipsen
Isabelle Dupin-Roger, Director, R&D External Innovation I Neuroscience and Immuno-inflammation, Servier
Dorothée Gueras Tricart, Head of Biotech division, Eurasanté
Monique Guis, External Innovation Immunology Director, Sanofi
Frank Hensel, Principal, High-Tech Gründerfonds
Dmitrij Hristodorov, Partner, Forbion
Lydia Kalafateli, Venture Developer, NLC Health
Alexandre Laly, Customer Application Consultant – Emerging Biotech, Merck
Esther Lange, Industry Liaison Manager, Ascenion
Marie-Ange N’Zoutani, Head of Acceleration office Sanofi Partnering, Sanofi
Richard Reschen, Associate Director, BD&L Europe, MSD
Olaf Ritzeler, BD&L, Director, Rare Diseases External Innovation / GLOBAL, Sanofi
Corinne Szilagyi, Senior Partner, Biotech Développement Conseils & Member of the Business Development Committee, France Biotech
Kristin Thompson, VP, Chief Business Officer, eureKARE
Joachim Vogt, Director, Search and Evaluation, Western Europe, AbbVie
Ulrich Zugel, Senior Director Emerging Science & Innovation Lead – Inflammation & Immunology Europe, Pfizer
Jean-Christophe Audonnet
Jean-Louis Hunault, President, SIMV
Theo Kanellos, Director Business Development and comercial Alliances, Zoetis
Jean-Pascal Marc, Corporate Product Innovation Director, Virbac
Edouard Timsit, Senior Innovation Scientist, Ceva Santé Animale